Drug pricing and reimbursement decision making systems in Mongolia View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-02-27

AUTHORS

Gereltuya Dorj, Bruce Sunderland, Tsetsegmaa Sanjjav, Gantuya Dorj, Byambatsogt Gendenragchaa

ABSTRACT

BACKGROUND: It is essential to allocate available resources equitably in order to ensure accessibility and affordability of essential medicines, especially in less fortunate nations with limited health funding. Currently, transparent and evidence based research is required to evaluate decision making regarding drug registration, drug pricing and reimbursement processes in Mongolia. OBJECTIVE: To assess the drug reimbursement system and discuss challenges faced by policy-makers and stakeholders. METHODS: The study has examined Mongolian administrative documents and directives for stakeholders and analysed published statistics. Experts and decision-makers were interviewed about the drug pricing and reimbursement processes in Mongolia. RESULTS: Decisions regarding Mongolian drug registration were based on commonly used criteria of quality, safety, efficacy plus some economic considerations. A total of 11.32 billion Mongolian National Tugrugs (MNT) [5.6 million United States Dollars (USD)] or 12.1% of total health expenditure was spent on patient reimbursement of essential drugs. The highest reimbursed drugs with respect to cost in 2014 were the cardiovascular drug group. Health insurance is compulsory for all citizens; in addition all insured patients have access to reimbursed drugs. However, the decision making process, in particular the level of reimbursement was limited by various barriers, including lack of evidence based data regarding efficacy and comparative cost-effectiveness analysis of drugs and decisions regarding reimbursement. CONCLUSIONS: Drug registration, pricing and reimbursement process in Mongolia show an increasing trend of drug registration and reimbursement rates, along with lack of transparency. Limited available data indicate that more evidence-based research studies are required in Mongolia to evaluate and improve the effectiveness of drug pricing and reimbursement policies. More... »

PAGES

11

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40545-017-0098-6

DOI

http://dx.doi.org/10.1186/s40545-017-0098-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1084253033

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28261487


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy and Biomedicine, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia", 
          "id": "http://www.grid.ac/institutes/grid.444534.6", 
          "name": [
            "Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy and Biomedicine, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dorj", 
        "givenName": "Gereltuya", 
        "id": "sg:person.01037011320.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037011320.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "School of Pharmacy, Faculty of Health Sciences, Curtin University of Technology, WA Perth, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1032.0", 
          "name": [
            "School of Pharmacy, Faculty of Health Sciences, Curtin University of Technology, WA Perth, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sunderland", 
        "givenName": "Bruce", 
        "id": "sg:person.01221353120.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221353120.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "School of Pharmacy and Biomedicine, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia", 
          "id": "http://www.grid.ac/institutes/grid.444534.6", 
          "name": [
            "School of Pharmacy and Biomedicine, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sanjjav", 
        "givenName": "Tsetsegmaa", 
        "id": "sg:person.0670407763.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670407763.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Epidemiology and Biostatistics, School of Public Health, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia", 
          "id": "http://www.grid.ac/institutes/grid.444534.6", 
          "name": [
            "Department of Epidemiology and Biostatistics, School of Public Health, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dorj", 
        "givenName": "Gantuya", 
        "id": "sg:person.014544655717.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014544655717.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "ISPOR Chapter Mongolia, Bayanzurkh district, 76-26, 13374 Ulaanbaatar, Mongolia", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "ISPOR Chapter Mongolia, Bayanzurkh district, 76-26, 13374 Ulaanbaatar, Mongolia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gendenragchaa", 
        "givenName": "Byambatsogt", 
        "id": "sg:person.015342236317.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015342236317.13"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00019053-200119110-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011251931", 
          "https://doi.org/10.2165/00019053-200119110-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1472-6963-13-379", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004860960", 
          "https://doi.org/10.1186/1472-6963-13-379"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-02-27", 
    "datePublishedReg": "2017-02-27", 
    "description": "BACKGROUND: It is essential to allocate available resources equitably in order to ensure accessibility and affordability of essential medicines, especially in less fortunate nations with limited health funding. Currently, transparent and evidence based research is required to evaluate decision making regarding drug registration, drug pricing and reimbursement processes in Mongolia.\nOBJECTIVE: To assess the drug reimbursement system and discuss challenges faced by policy-makers and stakeholders.\nMETHODS: The study has examined Mongolian administrative documents and directives for stakeholders and analysed published statistics. Experts and decision-makers were interviewed about the drug pricing and reimbursement processes in Mongolia.\nRESULTS: Decisions regarding Mongolian drug registration were based on commonly used criteria of quality, safety, efficacy plus some economic considerations. A total of 11.32 billion Mongolian National Tugrugs (MNT) [5.6 million United States Dollars (USD)] or 12.1% of total health expenditure was spent on patient reimbursement of essential drugs. The highest reimbursed drugs with respect to cost in 2014 were the cardiovascular drug group. Health insurance is compulsory for all citizens; in addition all insured patients have access to reimbursed drugs. However, the decision making process, in particular the level of reimbursement was limited by various barriers, including lack of evidence based data regarding efficacy and comparative cost-effectiveness analysis of drugs and decisions regarding reimbursement.\nCONCLUSIONS: Drug registration, pricing and reimbursement process in Mongolia show an increasing trend of drug registration and reimbursement rates, along with lack of transparency. Limited available data indicate that more evidence-based research studies are required in Mongolia to evaluate and improve the effectiveness of drug pricing and reimbursement policies.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s40545-017-0098-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1045870", 
        "issn": [
          "2052-3211"
        ], 
        "name": "Journal of Pharmaceutical Policy and Practice", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "keywords": [
      "drug registration", 
      "cardiovascular drug groups", 
      "comparative cost-effectiveness analysis", 
      "cost-effectiveness analysis", 
      "lack of evidence", 
      "drug groups", 
      "drug pricing", 
      "reimbursement process", 
      "evidence-based research studies", 
      "total health expenditure", 
      "essential drugs", 
      "essential medicines", 
      "health funding", 
      "reimbursement rates", 
      "drugs", 
      "limited available data", 
      "health insurance", 
      "reimbursed drugs", 
      "reimbursement policies", 
      "level of reimbursement", 
      "patient reimbursement", 
      "health expenditure", 
      "reimbursement system", 
      "reimbursement", 
      "efficacy", 
      "reimbursement decisions", 
      "drug reimbursement system", 
      "patients", 
      "available data", 
      "evidence", 
      "total", 
      "research studies", 
      "study", 
      "lack", 
      "medicine", 
      "safety", 
      "group", 
      "registration", 
      "insurance", 
      "levels", 
      "data", 
      "criteria", 
      "rate", 
      "decision making", 
      "expenditure", 
      "barriers", 
      "decisions", 
      "affordability", 
      "addition", 
      "access", 
      "quality", 
      "available resources", 
      "funding", 
      "effectiveness", 
      "analysis", 
      "experts", 
      "criteria of quality", 
      "trends", 
      "challenges", 
      "economic considerations", 
      "statistics", 
      "accessibility", 
      "system", 
      "research", 
      "consideration", 
      "process", 
      "stakeholders", 
      "respect", 
      "making", 
      "Directive", 
      "order", 
      "lack of transparency", 
      "policy", 
      "Mongolia", 
      "resources", 
      "administrative documents", 
      "documents", 
      "nations", 
      "citizens", 
      "transparency", 
      "pricing", 
      "less fortunate nations", 
      "fortunate nations", 
      "limited health funding", 
      "Mongolian administrative documents", 
      "Mongolian drug registration", 
      "Mongolian National Tugrugs", 
      "National Tugrugs", 
      "Tugrugs", 
      "more evidence-based research studies"
    ], 
    "name": "Drug pricing and reimbursement decision making systems in Mongolia", 
    "pagination": "11", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1084253033"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40545-017-0098-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28261487"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40545-017-0098-6", 
      "https://app.dimensions.ai/details/publication/pub.1084253033"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:45", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_752.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s40545-017-0098-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40545-017-0098-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40545-017-0098-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40545-017-0098-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40545-017-0098-6'


 

This table displays all metadata directly associated to this object as RDF triples.

197 TRIPLES      22 PREDICATES      118 URIs      108 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40545-017-0098-6 schema:about anzsrc-for:14
2 anzsrc-for:1402
3 schema:author N5fa650200467487cb090faacc1839ddd
4 schema:citation sg:pub.10.1186/1472-6963-13-379
5 sg:pub.10.2165/00019053-200119110-00004
6 schema:datePublished 2017-02-27
7 schema:datePublishedReg 2017-02-27
8 schema:description BACKGROUND: It is essential to allocate available resources equitably in order to ensure accessibility and affordability of essential medicines, especially in less fortunate nations with limited health funding. Currently, transparent and evidence based research is required to evaluate decision making regarding drug registration, drug pricing and reimbursement processes in Mongolia. OBJECTIVE: To assess the drug reimbursement system and discuss challenges faced by policy-makers and stakeholders. METHODS: The study has examined Mongolian administrative documents and directives for stakeholders and analysed published statistics. Experts and decision-makers were interviewed about the drug pricing and reimbursement processes in Mongolia. RESULTS: Decisions regarding Mongolian drug registration were based on commonly used criteria of quality, safety, efficacy plus some economic considerations. A total of 11.32 billion Mongolian National Tugrugs (MNT) [5.6 million United States Dollars (USD)] or 12.1% of total health expenditure was spent on patient reimbursement of essential drugs. The highest reimbursed drugs with respect to cost in 2014 were the cardiovascular drug group. Health insurance is compulsory for all citizens; in addition all insured patients have access to reimbursed drugs. However, the decision making process, in particular the level of reimbursement was limited by various barriers, including lack of evidence based data regarding efficacy and comparative cost-effectiveness analysis of drugs and decisions regarding reimbursement. CONCLUSIONS: Drug registration, pricing and reimbursement process in Mongolia show an increasing trend of drug registration and reimbursement rates, along with lack of transparency. Limited available data indicate that more evidence-based research studies are required in Mongolia to evaluate and improve the effectiveness of drug pricing and reimbursement policies.
9 schema:genre article
10 schema:inLanguage en
11 schema:isAccessibleForFree true
12 schema:isPartOf N02b15fc5d0e44a7eb46346f9fcf7dd0c
13 N3ba8bc331aae4fae8d96a88b4e6d3d2d
14 sg:journal.1045870
15 schema:keywords Directive
16 Mongolia
17 Mongolian National Tugrugs
18 Mongolian administrative documents
19 Mongolian drug registration
20 National Tugrugs
21 Tugrugs
22 access
23 accessibility
24 addition
25 administrative documents
26 affordability
27 analysis
28 available data
29 available resources
30 barriers
31 cardiovascular drug groups
32 challenges
33 citizens
34 comparative cost-effectiveness analysis
35 consideration
36 cost-effectiveness analysis
37 criteria
38 criteria of quality
39 data
40 decision making
41 decisions
42 documents
43 drug groups
44 drug pricing
45 drug registration
46 drug reimbursement system
47 drugs
48 economic considerations
49 effectiveness
50 efficacy
51 essential drugs
52 essential medicines
53 evidence
54 evidence-based research studies
55 expenditure
56 experts
57 fortunate nations
58 funding
59 group
60 health expenditure
61 health funding
62 health insurance
63 insurance
64 lack
65 lack of evidence
66 lack of transparency
67 less fortunate nations
68 level of reimbursement
69 levels
70 limited available data
71 limited health funding
72 making
73 medicine
74 more evidence-based research studies
75 nations
76 order
77 patient reimbursement
78 patients
79 policy
80 pricing
81 process
82 quality
83 rate
84 registration
85 reimbursed drugs
86 reimbursement
87 reimbursement decisions
88 reimbursement policies
89 reimbursement process
90 reimbursement rates
91 reimbursement system
92 research
93 research studies
94 resources
95 respect
96 safety
97 stakeholders
98 statistics
99 study
100 system
101 total
102 total health expenditure
103 transparency
104 trends
105 schema:name Drug pricing and reimbursement decision making systems in Mongolia
106 schema:pagination 11
107 schema:productId N77bdf574596a483bb5fb6d77b7757e99
108 Nb2b0104f85c84059acc317c539b74318
109 Ndb8fe7e76cd942b580ac185f644743a5
110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084253033
111 https://doi.org/10.1186/s40545-017-0098-6
112 schema:sdDatePublished 2022-01-01T18:45
113 schema:sdLicense https://scigraph.springernature.com/explorer/license/
114 schema:sdPublisher Nebe0302b13fd431499678ed6174c55f1
115 schema:url https://doi.org/10.1186/s40545-017-0098-6
116 sgo:license sg:explorer/license/
117 sgo:sdDataset articles
118 rdf:type schema:ScholarlyArticle
119 N02b15fc5d0e44a7eb46346f9fcf7dd0c schema:volumeNumber 10
120 rdf:type schema:PublicationVolume
121 N3ba8bc331aae4fae8d96a88b4e6d3d2d schema:issueNumber 1
122 rdf:type schema:PublicationIssue
123 N4a1ab7e853ce4e4e9cc39d794930f084 rdf:first sg:person.014544655717.42
124 rdf:rest Nbe7d55254eba431a9c1e910bfbc78f5b
125 N5fa650200467487cb090faacc1839ddd rdf:first sg:person.01037011320.24
126 rdf:rest N75618a088f2a43658a93f4a9cc6e0183
127 N75618a088f2a43658a93f4a9cc6e0183 rdf:first sg:person.01221353120.05
128 rdf:rest Ned4989fe6ed2412e91d0f422b331c32b
129 N77bdf574596a483bb5fb6d77b7757e99 schema:name dimensions_id
130 schema:value pub.1084253033
131 rdf:type schema:PropertyValue
132 Nb2b0104f85c84059acc317c539b74318 schema:name pubmed_id
133 schema:value 28261487
134 rdf:type schema:PropertyValue
135 Nbe7d55254eba431a9c1e910bfbc78f5b rdf:first sg:person.015342236317.13
136 rdf:rest rdf:nil
137 Ndb8fe7e76cd942b580ac185f644743a5 schema:name doi
138 schema:value 10.1186/s40545-017-0098-6
139 rdf:type schema:PropertyValue
140 Nebe0302b13fd431499678ed6174c55f1 schema:name Springer Nature - SN SciGraph project
141 rdf:type schema:Organization
142 Ned4989fe6ed2412e91d0f422b331c32b rdf:first sg:person.0670407763.76
143 rdf:rest N4a1ab7e853ce4e4e9cc39d794930f084
144 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
145 schema:name Economics
146 rdf:type schema:DefinedTerm
147 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
148 schema:name Applied Economics
149 rdf:type schema:DefinedTerm
150 sg:journal.1045870 schema:issn 2052-3211
151 schema:name Journal of Pharmaceutical Policy and Practice
152 schema:publisher Springer Nature
153 rdf:type schema:Periodical
154 sg:person.01037011320.24 schema:affiliation grid-institutes:grid.444534.6
155 schema:familyName Dorj
156 schema:givenName Gereltuya
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037011320.24
158 rdf:type schema:Person
159 sg:person.01221353120.05 schema:affiliation grid-institutes:grid.1032.0
160 schema:familyName Sunderland
161 schema:givenName Bruce
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221353120.05
163 rdf:type schema:Person
164 sg:person.014544655717.42 schema:affiliation grid-institutes:grid.444534.6
165 schema:familyName Dorj
166 schema:givenName Gantuya
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014544655717.42
168 rdf:type schema:Person
169 sg:person.015342236317.13 schema:affiliation grid-institutes:None
170 schema:familyName Gendenragchaa
171 schema:givenName Byambatsogt
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015342236317.13
173 rdf:type schema:Person
174 sg:person.0670407763.76 schema:affiliation grid-institutes:grid.444534.6
175 schema:familyName Sanjjav
176 schema:givenName Tsetsegmaa
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670407763.76
178 rdf:type schema:Person
179 sg:pub.10.1186/1472-6963-13-379 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004860960
180 https://doi.org/10.1186/1472-6963-13-379
181 rdf:type schema:CreativeWork
182 sg:pub.10.2165/00019053-200119110-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011251931
183 https://doi.org/10.2165/00019053-200119110-00004
184 rdf:type schema:CreativeWork
185 grid-institutes:None schema:alternateName ISPOR Chapter Mongolia, Bayanzurkh district, 76-26, 13374 Ulaanbaatar, Mongolia
186 schema:name ISPOR Chapter Mongolia, Bayanzurkh district, 76-26, 13374 Ulaanbaatar, Mongolia
187 rdf:type schema:Organization
188 grid-institutes:grid.1032.0 schema:alternateName School of Pharmacy, Faculty of Health Sciences, Curtin University of Technology, WA Perth, Australia
189 schema:name School of Pharmacy, Faculty of Health Sciences, Curtin University of Technology, WA Perth, Australia
190 rdf:type schema:Organization
191 grid-institutes:grid.444534.6 schema:alternateName Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy and Biomedicine, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia
192 Department of Epidemiology and Biostatistics, School of Public Health, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia
193 School of Pharmacy and Biomedicine, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia
194 schema:name Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy and Biomedicine, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia
195 Department of Epidemiology and Biostatistics, School of Public Health, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia
196 School of Pharmacy and Biomedicine, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia
197 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...